Our Therapeutic Areas

For more than 35 years, Gilead has discovered, developed and delivered innovative medicines in areas of great unmet medical need. Our ability to translate science into once-impossible advances has led to the commercialization of more than 29 life-changing therapies. Today, we have a robust portfolio and pipeline spanning virology, oncology and inflammation. We will continue relentlessly innovating in these therapeutic areas to transform care for people living with HIV, viral hepatitis, COVID-19, cancer, inflammatory diseases and other conditions.

Transforming the Landscape of HIV Care

Gilead has helped transform HIV into a treatable, preventable, chronic condition for millions of people. Working in close partnership with the HIV community, we’ve pioneered innovations that were once thought impossible – from the first single-tablet regimen to treat HIV, to the first oral therapy to prevent HIV infection, and the first twice-yearly long-acting injectable HIV treatment medication.

Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world.

Beyond the science, through partnerships and collaborations, we aim to improve education, expand access and address barriers to care, including stigma and discrimination, with the goal of ending the HIV epidemic for everyone, everywhere.

Taking on Hepatitis C, B, and D

Over the past ten years, we have helped cure millions of people with chronic hepatitis C virus (HCV). We continue to work toward the WHO’s goal of eliminating HCV as a public health problem by 2030 by working with stakeholders to help address the needs of the most vulnerable and disproportionally impacted communities.

Beyond HCV, we provide treatment options for people with hepatitis B (HBV) and D (HDV). We’ve been on the front lines of improving HBV care for over 20 years and added a first-in-class HDV treatment, conditionally approved in Europe, which we are working to make available worldwide.

Innovating to Treat COVID-19

When the COVID-19 outbreak began to emerge, we responded quickly to advance our then-investigational antiviral which had shown potential against other coronaviruses in laboratory and preclinical experiments, deploying decades of antiviral expertise and significant internal resources to help patients and communities working to ease the burden of the pandemic. Today, more than 13 million people globally have received our COVID-19 treatment. Gilead also signed non-exclusive voluntary licensing agreements with generic manufacturers to further expand supply of the product for distribution in 125+ countries and regions, nearly all of which are resource limited.

Advancing Transformative Cancer Science

We have purposefully built our oncology pipeline and by 2030, we aim to deliver 20+ indication approvals for therapies that could transform care in breast, lung, bladder and blood cancers. Our ambition is to positively impact the lives of more than 500,000 people with cancer around the world.

Our team at Kite is singularly focused on cell therapies which we believe have the potential to change the way cancer – and potentially other diseases – are treated.

Over the past few years, Gilead and Kite have received eight indication approvals in oncology, including medicines for difficult-to-treat metastatic cancers and cell therapies. Our expansive early-stage pipeline is designed to fuel a durable late-phase portfolio with more than 25 unique combination studies.

Developing Innovative Therapies for Inflammation

Gilead is researching new treatments to help address the needs of people living with inflammatory and fibrotic diseases, including inflammatory bowel disease, lupus, rheumatoid arthritis, atopic dermatitis and nonalcoholic steatohepatitis. Leveraging our extensive expertise in immunology and network of partnerships, we are advancing a range of early-stage programs to help meet these chronic conditions and the toll they take on patients’ lives.

A Historical Commitment Against Invasive Fungal Infections

For 30 years, Gilead has been invested in the treatment of invasive fungal infections, in particular aspergillosis, candidiasis, mucormycosis and cryptococcal meningitis. Gilead continues to work to improve access to antifungal treatments for all people in need.